MAPK
MAPKs are a family of protein kinases involved in a variety of cellular processes, including growth, proliferation, differentiation, and stress responses. The MAPK signaling pathway consists of several tiers, including ERK, JNK, and p38 MAPKs, each playing distinct roles in cellular function. Dysregulation of MAPK signaling is linked to cancer, inflammatory diseases, and metabolic disorders. At CymitQuimica, we offer a wide array of MAPK inhibitors and activators to support your research in cell biology, signal transduction, and disease mechanisms.
Found 897 products of "MAPK"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
KRAS inhibitor-31
CAS:KRAS inhibitor-31 (compound 33), a potent agent targeting KRAS, exhibits K D (SPR) values of 0.019 nM for KRas G12D, 0.019 nM for KRas G12C, and 0.096 nM for KRas G12V, illustrating its efficacy across these variants.Formula:C33H30F3N5O4Color and Shape:SolidMolecular weight:617.62PF-03715455
CAS:PF-03715455 is a potent p38 MAPK inhibitor, reducing TNFα in blood (IC50=1.7 nM) with selectivity for p38α, and may treat COPD.Formula:C35H34ClN7O3S2Purity:98%Color and Shape:SolidMolecular weight:700.27PS-166276
CAS:PS-166276 is a potent p38 inhibitor with low cytotoxicity. It exhibits an IC50 value of 28 nM against p38 kinase and an IC50 of 170 nM in the THP-1 TNFα assay.Formula:C20H30N8OColor and Shape:SolidMolecular weight:398.51Luvometinib
CAS:Luvometinib is an inhibitor of the mitogen-activated protein kinase (MEK) with antitumor activity.Formula:C26H22F2IN5O4SColor and Shape:SolidMolecular weight:665.45KRas G12C inhibitor 2
CAS:KRas G12C inhibitor 2 is a compound that inhibits KRas G12C.Formula:C32H37N7O3Purity:98%Color and Shape:SolidMolecular weight:567.68FMK-MEA
CAS:FMK-MEA is a potent and selective p90 Ribosomal S6 Kinase (RSK) inhibitor.Formula:C21H26FN5O2Purity:98%Color and Shape:SolidMolecular weight:399.46KRAS G12D inhibitor 26
CAS:KRAS G12D inhibitor 26 (Compound 64B) is an inhibitor of KRAS G12D with an IC50 ≤ 100 nM.Formula:C35H44ClFN8O2Purity:99.93%Color and Shape:SolidMolecular weight:663.23SR-302
CAS:SR-302 is a potent and selective inhibitor of DDR/p38, with IC50 values of 0.125 μM for p38α, 0.023 μM for DDR1, and 0.018 μM for DDR2. It is utilized in research related to fibrotic diseases, such as kidney and lung fibrosis, atherosclerosis, and various types of cancer.Formula:C32H42N6O5SColor and Shape:SolidMolecular weight:622.778(R)-STU104-d6
CAS:(R)-STU104-d6 is a deuterium-labeled variant of (R)-STU104. This compound acts as a potent and orally active inhibitor of the interaction between TAK1 and MKK3 proteins, exhibiting IC50 values of 0.58 μM for TNF-α and 4.0 μM for MKK3 phosphorylation. By binding to MKK3, (R)-STU104 hinders TAK1's ability to phosphorylate MKK3, thereby disrupting the TAK1/MKK3/p38/MnK1/MK2/elF4E signaling pathway. It is utilized in research related to ulcerative colitis.Formula:C18H182D6O4Color and Shape:SolidMolecular weight:304.37(S)-JDQ-443
CAS:(S)-JDQ-443, an isomer of JDQ-443, is a selective, potent oral KRAS G12C inhibitor with antitumor properties.Formula:C29H28ClN7OColor and Shape:SolidMolecular weight:526.03MRTX-EX185
MRTX-EX185 inhibits GDP-KRAS/G12D; IC50=90 nM on G12D. It also binds GDP-HRAS.Formula:C33H33FN6O2Color and Shape:SolidMolecular weight:564.65KRASG12C IN-15
CAS:KRASG12C IN-15 (Compound 21) is an orally active KRASG12C inhibitor that effectively blocks SOS1-mediated GDP/GTP exchange with an IC50 of 19 nM. It inhibits ERK phosphorylation with an IC50 of 0.051 μM and reduces the viability of KRASG12C mutant MIA PaCa-2 cells with an IC50 of 0.023 μM. Additionally, KRASG12C IN-15 demonstrates antitumor activity in a MIA PaCa-2 xenograft mouse model.Formula:C31H32FN3O2Color and Shape:SolidMolecular weight:497.603KRAS G12C inhibitor 37
CAS:KRAS G12C inhibitor 37 targets a key signaling protein, showing promise for cancer research involving KRAS G12C.Formula:C35H39F3N8O2Color and Shape:SolidMolecular weight:660.73(rel)-AR234960
CAS:(rel)-AR234960 is an active relative configuration of AR234960. AR234960 is a non-peptide agonist of MAS.Formula:C27H30FN5O5SColor and Shape:SolidMolecular weight:555.63p38 MAPK-IN-6
CAS:p38 MAPK-IN-6 (compound c47) is an inhibitor of p38 MAPK, exhibiting a 14% inhibition rate at a concentration of 10 μM.Formula:C16H14BrN3OS2Color and Shape:SolidMolecular weight:408.336JH295 hydrate
JH295 hydrate: potent, irreversible Nek2 inhibitor (IC50 = 770 nM), selective, doesn't target Cdk1, Aurora B or Plk1.Formula:C18H18N4O3Color and Shape:SolidMolecular weight:338.36JD118
CAS:JD118 is an inhibitor of JNK. It effectively suppresses the activity of JNK1 and the expression of cJun (1 - 135).Formula:C13H12N4S2Color and Shape:SolidMolecular weight:288.391JNK-1-IN-5
CAS:JNK-1-IN-5 (Compound 14) is a potent JNK1 inhibitor with sub-nanomolar efficacy. It effectively inhibits TGF-β-induced epithelial-mesenchymal transition and shows promise for research targeting JNK1 as an anti-pulmonary fibrosis agent.Formula:C23H21BrN6O3Color and Shape:SolidMolecular weight:509.355XMU-MP-9
CAS:XMU-MP-9, a bifunctional compound, targets the C2 domain of Nedd4-1 and the allosteric site of K-Ras. It enhances the interaction and induces conformational changes within the Nedd4-1/K-Ras complex. Furthermore, XMU-MP-9 facilitates the ubiquitination and degradation of various K-Ras mutants and inhibits the proliferation of cells with these mutants. This compound is useful in cancer research.Formula:C19H13ClFN3OSColor and Shape:SolidMolecular weight:385.84SOS1 activator 2
CAS:SOS1 activator 2 (Compound 65) is a benzothiazole derivative and an activator of SOS1. It demonstrates a high binding affinity for SOS1, with a Kd of 9 nM. By modulating the Ras-ERK signaling pathway, SOS1 activator 2 is suitable for tumor research.Formula:C26H28ClFN6Color and Shape:SolidMolecular weight:478.992
